

Biomet, Inc.
Other Financial Information
Sales by Product Category
(in millions, except percentages, unaudited)
(percentages represent year-over-year growth rates)

	Q1 FY 2011				Q2 FY 2011				Q3 FY 2011				Q4 FY 2011				YTD FY 2011			
	Worldwide Reported Q1 - FY 2011	Worldwide Reported Growth %	Worldwide CC Growth %	United States Growth %	Worldwide Reported Q2 - FY 2011	Worldwide Reported Growth %	Worldwide CC Growth %	United States Growth %	Worldwide Reported Q3 - FY 2011	Worldwide Reported Growth %	Worldwide CC Growth %	United States Growth %	Worldwide Reported Q4 - FY 2011	Worldwide Reported Growth %	Worldwide CC Growth %	United States Growth %	Worldwide Reported YTD - FY 2011	Worldwide Reported Growth %	Worldwide CC Growth %	United States Growth %
Large Joint Reconstructive	\$ 379.7	2 %	3 %	5 %	\$ 422.8	- %	2 %	1 %	\$ 402.6	(1) %	(1) %	(3) %	\$ 425.5	3 %	(1) %	(3) %	\$ 1,630.6	1 %	1 %	- %
Knees		4 %	5 %	6 %		2 %	3 %	3 %		(2) %	(1) %	(5) %		2 %	(1) %	(5) %		1 %	1 %	- %
Hips		- %	2 %	4 %		(1) %	- %	- %		- %	- %	- %		3 %	- %	- %		1 %	- %	1 %
Bone Cement and Other		(7) %	(4) %	- %		(4) %	(1) %	(2) %		1 %	2 %	3 %		6 %	2 %	2 %		(1) %	- %	1 %
Sports, Extremities, Trauma (S.E.T.)	72.1	13 %	14 %	21 %	75.7	11 %	12 %	19 %	80.2	12 %	13 %	16 %	84.3	6 %	4 %	8 %	312.3	10 %	10 %	16 %
Sports Medicine		15 %	17 %	18 %		16 %	17 %	17 %		20 %	21 %	16 %		13 %	11 %	8 %		16 %	16 %	14 %
Extremities		25 %	27 %	40 %		21 %	23 %	36 %		18 %	18 %	25 %		17 %	15 %	22 %		20 %	20 %	30 %
Trauma		(4) %	(3) %	2 %		(10) %	(9) %	(5) %		(6) %	(5) %	- %		(17) %	(20) %	(14) %		(10) %	(10) %	(4) %
Spine & Bone Healing	84.7	(3) %	(2) %	(2) %	81.2	(5) %	(4) %	(3) %	80.5	(1) %	- %	(2) %	80.0	(11) %	(12) %	(13) %	326.4	(5) %	(5) %	(5) %
Spine		(1) %	- %	1 %		(3) %	(3) %	- %		1 %	1 %	(1) %		(10) %	(10) %	(12) %		(3) %	(3) %	(3) %
Bone Healing		(7) %	(7) %	(7) %		(8) %	(8) %	(8) %		(5) %	(5) %	(5) %		(15) %	(15) %	(15) %		(9) %	(9) %	(9) %
Dental	56.6	(2) %	(1) %	3 %	71.7	1 %	3 %	(2) %	67.2	5 %	6 %	4 %	74.0	2 %	(2) %	6 %	269.5	2 %	2 %	3 %
Other	47.6	1 %	3 %	(1) %	46.9	(5) %	(3) %	- %	47.5	2 %	2 %	(1) %	51.4	10 %	7 %	- %	193.4	2 %	2 %	- %
Net Sales	\$ 640.7	2 %	3 %	5 %	\$ 698.3	- %	2 %	2 %	\$ 678.0	1 %	2 %	- %	\$ 715.2	2 %	(1) %	(3) %	\$ 2,732.2	1 %	1 %	1 %

	Q1 FY 2012			
	Worldwide Reported Q1 - FY 2012	Worldwide Reported Growth %	Worldwide CC Growth %	United States Growth %
Large Joint Reconstructive	\$ 397.0	5 %	- %	(1) %
Knees		2 %	(2) %	(4) %
Hips		7 %	2 %	3 %
Bone Cement and Other		10 %	3 %	7 %
Sports, Extremities, Trauma (S.E.T.)	80.1	11 %	8 %	8 %
Sports Medicine		12 %	9 %	1 %
Extremities		19 %	16 %	21 %
Trauma		(2) %	(6) %	(6) %
Spine & Bone Healing	76.1	(10) %	(11) %	(10) %
Spine		(10) %	(11) %	(10) %
Bone Healing		(11) %	(11) %	(11) %
Dental	59.3	5 %	(1) %	7 %
Other	52.1	9 %	6 %	3 %
Net Sales	\$ 664.6	4 %	- %	(1) %

Biomet, Inc.

Other Financial Information

Days Sales Outstanding ("DSO")

(in millions, except DSO's)

(Unaudited)

	3 Mos Ended 8/31/2009	3 Mos Ended 11/30/2009	3 Mos Ended 2/28/2010	3 Mos Ended 5/31/2010	3 Mos Ended 8/31/2010	3 Mos Ended 11/30/2010	3 Mos Ended 2/28/2011	3 Mos Ended 5/31/2011	3 Mos Ended 8/31/2011
Accounts Receivable, Net	\$ 498.6	\$ 558.9	\$ 522.7	<u>\$ 452.5</u>	<u>\$ 429.0</u>	<u>\$ 475.4</u>	<u>\$ 480.5</u>	<u>\$ 480.1</u>	<u>\$ 457.8</u>
Less: Greece Receivables, Net ⁽¹⁾	<u>(33.8)</u>	<u>(33.8)</u>	<u>(33.8)</u>						
Accounts Receivable, Net (Excluding Greece)	<u>\$ 464.8</u>	<u>\$ 525.1</u>	<u>\$ 488.9</u>						
Quarter to Date (QTD) Net Sales	\$ 630.1	\$ 695.6	\$ 669.8	\$ 702.5	\$ 640.7	\$ 698.3	\$ 678.0	\$ 715.2	\$ 664.6
QTD Calculated DSO's:									
Including Accounts Greece Receivables ⁽²⁾	72.2	73.3	71.2						
Excluding Greece Accounts Receivables ⁽³⁾	67.3	68.9	66.6	58.8	61.1	62.1	64.7	61.3	62.9
	<u>12 Mos Ended 5/31/2010</u>	<u>12 Mos Ended 5/31/2011</u>							
Accounts Receivable, Net	<u>\$ 452.5</u>	<u>\$ 480.1</u>							
Year to Date (YTD) Net Sales	\$ 2,698.0	\$ 2,732.2							
YTD Average Accounts Receivable, Net	\$ 481.8	\$ 466.3							
YTD Calculated DSO's ⁽⁴⁾	65.2	62.3							

(1) The Company received zero coupon bonds from the Greece government with a fair market value at issuance of \$33.8 during fiscal 2011. The Company estimated this amount to be \$38.9 at 5/31/10 and reclassified this amount to investments due to the proposal of the Greece government to settle certain debts with these bonds. The Company reclassified the actual amount received of \$33.8 during the first 3 quarters of fiscal 2010 to show comparable DSO calculations in the current year.

(2) QTD DSO's including Greece accounts receivables represent net accounts receivable divided by QTD net sales multiplied by 91.25 days.

(3) QTD DSO's excluding Greece accounts receivables represent net accounts receivable (excluding Greece) divided by QTD net sales multiplied by 91.25 days.

(4) YTD DSO's represent YTD average net accounts receivable divided by YTD net sales multiplied by 365 days.

Biomet, Inc.
Other Financial Information
Cost of Sales Reconciled to Cost of Sales, Excluding Special Items
Inventory Turns
(in millions, except inventory turns and percentages)
(Unaudited)

	3 Mos Ended 8/31/2011	12 Mos Ended 5/31/2011	9 Mos Ended 2/28/2011	6 Mos Ended 11/30/2010	3 Mos Ended 8/31/2010	12 Mos Ended 5/31/2010	9 Mos Ended 2/28/2010	6 Mos Ended 11/30/2009	3 Mos Ended 8/31/2009
Cost of Sales	\$215.3	\$838.7	\$609.6	\$401.5	\$194.0	\$819.9	\$595.1	\$398.9	\$185.3
<i>Less Special Items:</i>									
Purchase accounting depreciation	4.6	17.8	13.3	8.8	4.4	17.8	13.3	8.9	4.5
Stock-based compensation expense	0.3	0.6	0.9	0.6	0.3	1.7	1.2	0.9	0.4
Litigation settlements and reserves and other legal fees		0.4	0.2			(7.0)	(6.9)	(1.1)	
Operational restructuring and consulting expenses related to operational initiatives (severance, building impairments, abnormal manufacturing variances and other related costs)	10.2	31.9	19.6	12.5	6.8	32.1	18.5	15.6	2.9
Cost of Sales, Excluding Special Items	\$200.2	\$788.0	\$575.6	\$379.6	\$182.5	\$775.3	\$569.0	\$374.6	\$177.5
	<u>8/31/2011</u>	<u>5/31/2011</u>	<u>2/28/2011</u>	<u>11/30/2010</u>	<u>8/31/2010</u>	<u>5/31/2010</u>	<u>2/28/2010</u>	<u>11/30/2009</u>	<u>8/31/2009</u>
Net Inventory Balances	\$581.5	\$582.5	\$591.6	\$571.4	\$534.9	\$507.3	\$536.8	\$555.6	\$542.9
	<u>8/31/2011</u>	<u>5/31/2011</u>	<u>2/28/2011</u>	<u>11/30/2010</u>	<u>8/31/2010</u>	<u>5/31/2010</u>	<u>2/28/2010</u>	<u>11/30/2009</u>	<u>8/31/2009</u>
Reported Inventory Turns (1)	1.5407	1.5392	1.4789	1.4596	1.5375	1.5902	1.6422	1.4547	1.5299
Adjusted Inventory Turns (2)	1.4434	1.4461	1.3859	1.3847	1.4479	1.5037	1.4234	1.3725	1.3122
Increase (decrease) from prior year end (Reported)	0.10 %	(3.21) %	(7.00) %	(8.21) %	(3.31) %				
Increase (decrease) from prior year end (Adjusted)	(0.19) %	(3.83) %	(7.83) %	(7.91) %	(3.71) %				

(1) Reported Inventory Turns represent the last 12 months cost of sales divided by average year over year inventory balances.

(2) Adjusted Inventory Turns represent the last 12 months cost of sales, adjusted for special items noted above, divided by average year over year inventory balances.